Pharmacological treatment of depression;Tratamiento farmacológico de la depresión

Revista Clinica Espanola

Volumn 205, Issue 5, 2005, Pages 233-240

  Saiz Ruiz, J ^a   Montes Rodriguez J M ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Antidepressants; Depression; Resistant depression

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIANSERIN; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; REBOXETINE; SERTRALINE; VENLAFAXINE;

DEPRESSION; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; PREVALENCE; REVIEW; SOCIOECONOMICS;

EID: 20444466477     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13075575     Document Type: Review

References (29)

1. Lépine JP, Gastpar M, Mendlewicz J, Tylee A. Depresión in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol. 1997;12:19-29.
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughers M, Eshleman S, et al: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States; results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
3. Murray CJL, López AD. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science. 1996;274:740-3.
4. Kuhn R. Uber die Behandlug depressiver Zustände mit einen Iminodibenzylderivat (G22355). Schweiz Med Wochenschr. 1957;87:1135-40.
5. Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin and digoxin. Acta Psychiatr Sand. 1989;350:102-6.
6. Montejo AL, Llorca G, Izquierdo JA, Rico-Villademoros F. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1,022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001;62 Supl 3: 10-21.
7. Wade AG, Lemming O, Hedegaard K. Escitalopram 10 mg/day is effective and well-tolerated in a placebo-controlled study in depression in Primary Care. Int Clin Psychopharmacol. 2002;17:95-102.
8. Dingemanse J. An update of recent moclobemide interaction data. Int Clin Psychopharmacol. 1993;7:167-80.
9. Schatzberg AF. Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. J Clin Psychiatry. 2003;64 Supl 13:30-7.
10. Anderson IM. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord. 2000;58:19-36.
11. Montes JM, Ferrando L, Saiz-Ruiz J. Remission in major depresión with two antidepressant mechanisms: results from a naturalistic study. J Affect Disord. 2004;79:229-34.
12. Lonnqvist J, Sihvo S, Syvalahti E, Kiviruusu O. Moclobemide and fluoxetine in atypical depression: a double-blind trial. J Affect Disord. 1994;32:169-77.
13. Partonen T, Lonnqvist J. Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord. 1996;41:93-9.
14. Naranjo CA, Knoke DM. The role of serotonin reuptake inhibitors in reducing alcohol consumption. J Clin Psychiatry, 2001;62 Suppl 20:18-25.
15. Cohen LS, Nonacs R, Viguera AC, Reminick A. Diagnosis and treatment of depresión during pregnancy. CNS Spectrums. 2004; 9:209-16.
16. Nulman I, Rovet J, Stewart D, Wolpin J, Gardner HA, Theis IG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med. 1997;336:258-62.
17. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004; 363(9418):1341-5.
18. Wong IC, Besag FM, Santosh PJ, Murray ML. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf. 2004;27(13): 991-1000.
19. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, et al. Major depressive disorder: a prospective study of subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97-108.
20. Vallejo J, Urretavizcaya M. Tratamiento de las depresiones resistentes. En: Vallejo J, Gastó C, editores. Trastornos afectivos: ansiedad y depresión. Barcelona: Masson; 2000.
21. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004;65(9):1190-6.
22. Saiz J, Ibáñez A, Díaz-Marsá M, Arias F, Padín J, Martín-Carrasco M, et al. Eficacia de venlafaxina en pacientes depresivos resistentes o que no toleran inhibidores selectivos de la recaptación de serotonina, Psiquiatría Biológica. 1999;6(3):106-12.
23. O'Flanagan P. Clomipramine infusion and lithium carbonate: a synergistic effect? Lancet. 1973;2:974.
24. Lam RW, Wan DDC, Cohen NL, Kennedy SH. Combining antidepressants for treatment-resistant depression: a review. J Clin Psychiatry. 2002; 63:685-93.
25. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, et al. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry. 2001;158:131-4.
26. Hirose S, Ashby CR. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry. 2002;63:733-6.
27. Angst J. Natural history and epidemiology of depression. Results of community studies. En: Cobb J, Goeting N, editors. Prediction and treatment of recurrent depression. Southampton: Duphar Medical Relations; 1990.
28. Gonzales LR, Lewinsohn PM, Clarke GN. Longitudinal follow-up of unipolar depressives: an investigation of predictors of relapse. J Consult Clin Psychol. 1985;53:461-9.
29. Maj M, Veltro F, Pirozzi R, Lobrace S, Magliano L. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry. 1992;149:795-800.